MCID: MYL080
MIFTS: 29

Myalgic Encephalomyelitis/chronic Fatigue Syndrome

Categories: Rare diseases

Aliases & Classifications for Myalgic Encephalomyelitis/chronic Fatigue Syndrome

MalaCards integrated aliases for Myalgic Encephalomyelitis/chronic Fatigue Syndrome:

Name: Myalgic Encephalomyelitis/chronic Fatigue Syndrome 20
Chronic Fatigue Syndrome/ Myalgic Encephalomyelitis 20
Systemic Exertion Intolerance Disease 20
Me/cfs 20

Classifications:



Summaries for Myalgic Encephalomyelitis/chronic Fatigue Syndrome

GARD : 20 Myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS) is an umbrella term that includes both myalgic encephalomyelitis (ME) and chronic fatigue syndrome (CFS). It is a serious, chronic and complex disease that affects many systems of the body and can profoundly impact daily activities. The main symptom is disabling fatigue that does not improve with rest and lasts at least 6 months. Fatigue may get worse after activity, which is known as post-exertional malaise. Other signs and symptoms may include muscle pain, joint pain, concentration and memory problems, headaches, sleep problems, fever, sore throat, and/or tender lymph nodes. ME/CFS generally occurs in young adults (20 to 40 years of age) and is twice as common in women. The exact cause is not known, but symptoms may be triggered by an infection. Diagnosis can be difficult as there are no specific laboratory tests and the symptoms are common to a number of different illnesses. There is no cure or effective treatment for this condition but there are several clinical trials. While the term ME/CFS is widely used, there is still a debate in the medical literature about the relationship between myalgic encephalomyelitis and chronic fatigue syndrome and there is no universally accepted definition. The term "systemic exertion intolerance disease" has been proposed as new term for both diseases.

MalaCards based summary : Myalgic Encephalomyelitis/chronic Fatigue Syndrome, also known as chronic fatigue syndrome/ myalgic encephalomyelitis, is related to chronic fatigue syndrome and fibromyalgia. An important gene associated with Myalgic Encephalomyelitis/chronic Fatigue Syndrome is TRPM3 (Transient Receptor Potential Cation Channel Subfamily M Member 3), and among its related pathways/superpathways are Cytokine Signaling in Immune system and Immune response IFN alpha/beta signaling pathway. The drugs Cyclophosphamide and Acetylcysteine have been mentioned in the context of this disorder. Affiliated tissues include whole blood, eye and prostate.

Related Diseases for Myalgic Encephalomyelitis/chronic Fatigue Syndrome

Diseases related to Myalgic Encephalomyelitis/chronic Fatigue Syndrome via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 92)
# Related Disease Score Top Affiliating Genes
1 chronic fatigue syndrome 32.4 TRPM3 RNASEL
2 fibromyalgia 10.9
3 orthostatic intolerance 10.9
4 alpha/beta t-cell lymphopenia with gamma/delta t-cell expansion, severe cytomegalovirus infection, and autoimmunity 10.7
5 autonomic dysfunction 10.6
6 irritable bowel syndrome 10.6
7 multiple sclerosis 10.5
8 cytokine deficiency 10.5
9 anxiety 10.5
10 disease by infectious agent 10.5
11 physical disorder 10.5
12 postural orthostatic tachycardia syndrome 10.5
13 sleep disorder 10.5
14 chronic pain 10.5
15 autoimmune disease 10.4
16 migraine with or without aura 1 10.4
17 type 1 diabetes mellitus 10.4
18 lyme disease 10.4
19 endogenous depression 10.4
20 lactic acidosis 10.4
21 overgrowth syndrome 10.4
22 pfeiffer syndrome 10.2
23 arteries, anomalies of 10.2
24 erythermalgia, primary 10.2
25 hypercholesterolemia, familial, 1 10.2
26 ige responsiveness, atopic 10.2
27 celiac disease 1 10.2
28 body mass index quantitative trait locus 1 10.2
29 lipoprotein quantitative trait locus 10.2
30 coenzyme q10 deficiency disease 10.2
31 sleep apnea 10.2
32 alexithymia 10.2
33 pain agnosia 10.2
34 covid-19 10.2
35 bacterial infectious disease 10.2
36 rickets 10.2
37 q fever 10.2
38 primary biliary cholangitis 10.2
39 benign paroxysmal positional nystagmus 10.2
40 epicondylitis 10.2
41 mental depression 10.2
42 constipation 10.2
43 spondylosis 10.2
44 gastroenteritis 10.2
45 endometriosis 10.2
46 severe acute respiratory syndrome 10.2
47 mood disorder 10.2
48 systemic mastocytosis 10.2
49 mastocytosis 10.2
50 eosinophilic gastroenteritis 10.2

Graphical network of the top 20 diseases related to Myalgic Encephalomyelitis/chronic Fatigue Syndrome:



Diseases related to Myalgic Encephalomyelitis/chronic Fatigue Syndrome

Symptoms & Phenotypes for Myalgic Encephalomyelitis/chronic Fatigue Syndrome

Drugs & Therapeutics for Myalgic Encephalomyelitis/chronic Fatigue Syndrome

Drugs for Myalgic Encephalomyelitis/chronic Fatigue Syndrome (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show all 31)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Cyclophosphamide Approved, Investigational Phase 2 50-18-0, 6055-19-2 2907
2
Acetylcysteine Approved, Investigational Phase 2 616-91-1 12035
3
Etanercept Approved, Investigational Phase 2 185243-69-0
4
rituximab Approved Phase 2 174722-31-7 10201696
5 Alkylating Agents Phase 2
6 Adrenocorticotropic Hormone Phase 1, Phase 2
7 Corticotropin-Releasing Hormone Phase 1, Phase 2
8 Antioxidants Phase 2
9 N-monoacetylcystine Phase 2
10 Anticonvulsants Phase 2
11 Pyridostigmine Bromide Phase 2 101-26-8
12 Neurotransmitter Agents Phase 2
13 Cholinergic Agents Phase 2
14 Cholinesterase Inhibitors Phase 2
15 Bromides Phase 2
16 Anti-Inflammatory Agents Phase 2
17 Analgesics, Non-Narcotic Phase 2
18 Immunosuppressive Agents Phase 2
19 Gastrointestinal Agents Phase 2
20 Immunoglobulins Phase 2
21 Anti-Inflammatory Agents, Non-Steroidal Phase 2
22 Antirheumatic Agents Phase 2
23 Analgesics Phase 2
24 Antibodies Phase 2
25 Immunologic Factors Phase 2
26 Pharmaceutical Solutions Phase 1
27
Naltrexone Approved, Investigational, Vet_approved 16590-41-3 5360515
28
Ethanol Approved 64-17-5 702
29 Acidophilus
30 Narcotics
31 Narcotic Antagonists

Interventional clinical trials:

(show all 23)
# Name Status NCT ID Phase Drugs
1 A Double-Blind, Randomized, Placebo-Controlled, Single-Center, Flexible Titration Study Evaluating the Efficacy of Solriamfetol in Treating Fatigue and Cognitive Symptoms in Adults Aged 18-65 Years With a Diagnosis of Myalgic Encephalomyelitis/Chronic Fatigue Syndrome Not yet recruiting NCT04622293 Phase 4 Solriamfetol Oral Tablet [Sunosi];Placebo
2 Cyclophosphamide in Myalgic Encephalopathy/ Chronic Fatigue Syndrome (ME/CFS). Part A: an Open Label Phase-II Study With Six Intravenous Cyclophosphamide Infusions Four Weeks Apart, and Follow-up for 12 Months Unknown status NCT02444091 Phase 2 Cyclophosphamide
3 Pilot Phase 1/2, Open-Label, Clinical Trial to Investigate CT38 in the Treatment of Myalgic Encephalomyelitis / Chronic Fatigue Syndrome Completed NCT03613129 Phase 1, Phase 2 CT38
4 Mechanistic Assessment of N-Acetylcysteine as an Antioxidant Therapy for Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS) Through Dose Response and Treatment Target Engagement Recruiting NCT04542161 Phase 2 NAC 900mg/day;NAC 3600mg/day;NAC 0mg/day (Placebo)
5 The Exercise Response to Pharmacologic Cholinergic Stimulation in Myalgic Encephalomyelitis / Chronic Fatigue Syndrome Enrolling by invitation NCT03674541 Phase 2 Pyridostigmine Bromide;Placebo
6 Tumor Necrosis Factor-alpha Inhibition Using Etanercept in Moderate and Serious Chronic Fatigue Syndrome/ Myalgic Encephalomyelitis (CFS/ME), Including in Patients With no Clinical Response After B-lymphocyte Depletion Using the Anti-CD20 Antibody Rituximab. Terminated NCT01730495 Phase 2 Etanercept
7 Reducing Orthostatic Intolerance With Oral Rehydration in Patients With Myalgic Encephalomyelitis/Chronic Fatigue Syndrome Active, not recruiting NCT02854683 Phase 1 Normal Saline
8 New MRT Imaging Biomarkers and Treatment With Kinetic Oscillatory Stimulation (KOS) in Nasal Cavity for Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS) Unknown status NCT03502044
9 ME/CFS: Activity Patterns and Autonomic Dysfunction Unknown status NCT02948556
10 Use of a Monitor in ME/CFS Unknown status NCT01908036
11 Sex Differences in Exercise-related Post-exertional Malaise in ME/CFS Unknown status NCT03331419
12 Hypermobility and Obstructions in the Craniocervical Region Among Patients With Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS) Completed NCT04399330
13 Psychological Wellbeing in Adults With Chronic Fatigue Syndrome/ Myalgic Encephalomyelitis Completed NCT02094820
14 Acceptance & Commitment Therapy for ME/CFS (Chronic Fatigue Syndrome) - an Open Case Trial Completed NCT03562325
15 Effect of Probiotic Food Supplement "GutMagnific™" in Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS), Also Known as Post-viral Fatigue Syndrome, and Comorbid Gastrointestinal Complications Recruiting NCT04741841
16 A Non-Interventional Pilot Study to Explore the Role of Gut Flora in Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS) Recruiting NCT04100915
17 Myalgic Encephalomyelitis/Chronic Fatigue Syndrome Recruiting NCT02669212
18 Assessment of Exercise Response in Chronic Fatigue Syndrome / Myalgic Encephalomyelitis. Recruiting NCT03675087
19 Probing Metabolism, Circulating Inflammatory Molecules, Extracellular Vesicles and Immune Dysregulation in Individual Immune Cells in ME/CFS Recruiting NCT04026425
20 Defining Autoimmune Aspects of Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS) Enrolling by invitation NCT03254823
21 The ME-SH (Myalgic Encephalomyelitis in Stockholm-Harvard) Study: Structural Problems in Brainstem and Cervical Spine Cord in Myalgic Encephalomyelitis/Chronic Fatigue Syndrome(ME/CFS) - a Case-control Study Not yet recruiting NCT04403854
22 The Influence of Epigenetic Modifications and Post-Exertional Malaise in People With Myalgic Encephalomyelitis/Chronic Fatigue Syndrome Not yet recruiting NCT04378634
23 The Immune Effects of Low-dose Naltrexone in People With Myalgic Encephalopathy/Chronic Fatigue Syndrome (ME/CFS) Suspended NCT02965768 Naltrexone HCl

Search NIH Clinical Center for Myalgic Encephalomyelitis/chronic Fatigue Syndrome

Genetic Tests for Myalgic Encephalomyelitis/chronic Fatigue Syndrome

Anatomical Context for Myalgic Encephalomyelitis/chronic Fatigue Syndrome

MalaCards organs/tissues related to Myalgic Encephalomyelitis/chronic Fatigue Syndrome:

40
Whole Blood, Eye, Prostate, T Cells, Endothelial, Hypothalamus

Publications for Myalgic Encephalomyelitis/chronic Fatigue Syndrome

Articles related to Myalgic Encephalomyelitis/chronic Fatigue Syndrome:

(show top 50) (show all 453)
# Title Authors PMID Year
1
Insights from Invasive Cardiopulmonary Exercise Testing of Patients with Myalgic Encephalomyelitis/Chronic Fatigue Syndrome. 61
33577778 2021
2
A systematic review of nutraceutical interventions for mitochondrial dysfunctions in myalgic encephalomyelitis/chronic fatigue syndrome. 61
33596913 2021
3
Are Circulating Fibroblast Growth Factor 21 and N-Terminal Prohormone of Brain Natriuretic Peptide Promising Novel Biomarkers in Myalgic Encephalomyelitis/Chronic Fatigue Syndrome? 61
33353469 2021
4
Measuring improvement and deterioration in myalgic encephalomyelitis/chronic fatigue syndrome: the pitfalls of the Chalder Fatigue Questionnaire. 61
33319615 2021
5
Open-label study with the monoamine stabilizer (-)-OSU6162 in myalgic encephalomyelitis/chronic fatigue syndrome. 61
33528911 2021
6
Off label use of Aripiprazole shows promise as a treatment for Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS): a retrospective study of 101 patients treated with a low dose of Aripiprazole. 61
33536023 2021
7
Hypothesis: Mechanisms That Prevent Recovery in Prolonged ICU Patients Also Underlie Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS). 61
33585528 2021
8
Homebound versus Bedridden Status among Those with Myalgic Encephalomyelitis/Chronic Fatigue Syndrome. 61
33498489 2021
9
Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS): Major Impact on Lives of Both Patients and Family Members. 61
33430175 2021
10
Myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS): Where will the drugs come from? 61
33529750 2021
11
Exercise modifies glutamate and other metabolic biomarkers in cerebrospinal fluid from Gulf War Illness and Myalgic encephalomyelitis / Chronic Fatigue Syndrome. 61
33440400 2021
12
Beyond bones: The relevance of variants of connective tissue (hypermobility) to fibromyalgia, ME/CFS and controversies surrounding diagnostic classification: an observational study. 61
33479068 2021
13
COVID-19 and chronic fatigue syndrome: Is the worst yet to come? 61
33401106 2021
14
The evidence base for physiotherapy in myalgic encephalomyelitis/chronic fatigue syndrome when considering post-exertional malaise: a systematic review and narrative synthesis. 61
33397399 2021
15
Myalgic Encephalomyelitis/Chronic Fatigue Syndrome: The Human Herpesviruses Are Back! 61
33572802 2021
16
Modulatory effects of cognitive exertion on regional functional connectivity of the salience network in women with ME/CFS: A pilot study. 61
33556867 2021
17
In-Depth Analysis of the Plasma Proteome in ME/CFS Exposes Disrupted Ephrin-Eph and Immune System Signaling. 61
33572894 2021
18
Sex-Based Differences in Plasma Autoantibodies to Central Nervous System Proteins in Gulf War Veterans versus Healthy and Symptomatic Controls. 61
33498629 2021
19
The draft updated NICE guidance for ME/CFS highlights the unreliability of subjective outcome measures in non-blinded trials. 61
33506707 2021
20
The Prospects of the Two-Day Cardiopulmonary Exercise Test (CPET) in ME/CFS Patients: A Meta-Analysis. 61
33327624 2020
21
A Literature Review of GP Knowledge and Understanding of ME/CFS: A Report from the Socioeconomic Working Group of the European Network on ME/CFS (EUROMENE). 61
33374291 2020
22
A concerning display of medical indifference: reply to 'Chronic fatigue syndrome and an illness-focused approach to care: controversy, morality and paradox'. 61
32601171 2020
23
Risks for Developing ME/CFS in College Students Following Infectious Mononucleosis: A Prospective Cohort Study. 61
33367564 2020
24
Mitochondria and immunity in chronic fatigue syndrome. 61
32470498 2020
25
Myalgic Encephalomyelitis/Chronic Fatigue Syndrome: Organic Disease or Psychosomatic Illness? A Re-Examination of the Royal Free Epidemic of 1955. 61
33375343 2020
26
Fallout from the COVID-19 pandemic - should we prepare for a tsunami of post viral depression? 61
32408926 2020
27
Could Cognitive Behavioural Therapy Be an Effective Treatment for Long COVID and Post COVID-19 Fatigue Syndrome? Lessons from the Qure Study for Q-Fever Fatigue Syndrome. 61
33322316 2020
28
Elevated Perceived Exertion in People with Myalgic Encephalomyelitis/Chronic Fatigue Syndrome and Fibromyalgia: A Meta-analysis. 61
32555018 2020
29
Patients' experiences and effects of non-pharmacological treatment for myalgic encephalomyelitis/chronic fatigue syndrome - a scoping mixed methods review. 61
32432991 2020
30
Circulating leptin levels in patients with myalgic encephalomyelitis, chronic fatigue syndrome or fibromyalgia: a systematic review protocol. 61
33136710 2020
31
Role of mitochondria, oxidative stress and the response to antioxidants in myalgic encephalomyelitis/chronic fatigue syndrome: a possible approach to SARS-CoV-2 'long-haulers'? 61
33251031 2020
32
Changes in DNA methylation profiles of myalgic encephalomyelitis/chronic fatigue syndrome patients reflect systemic dysfunctions. 61
33148325 2020
33
Altered Structural Brain Networks Related to Adrenergic/Muscarinic Receptor Autoantibodies in Chronic Fatigue Syndrome. 61
32609410 2020
34
Meta-analysis investigating post-exertional malaise between patients and controls. 61
29974812 2020
35
Profile of circulating microRNAs in myalgic encephalomyelitis and their relation to symptom severity, and disease pathophysiology. 61
33184353 2020
36
Accurate and objective determination of myalgic encephalomyelitis/chronic fatigue syndrome disease severity with a wearable sensor. 61
33168001 2020
37
Deep phenotyping of myalgic encephalomyelitis/chronic fatigue syndrome in Japanese population. 61
33199820 2020
38
Correction to: A systematic review of mitochondrial abnormalities in myalgic encephalomyelitis/chronic fatigue syndrome/systemic exertion intolerance disease. 61
33109201 2020
39
Cytokine profiling of extracellular vesicles isolated from plasma in myalgic encephalomyelitis/chronic fatigue syndrome: a pilot study. 61
33046133 2020
40
The Lonely, Isolating, and Alienating Implications of Myalgic Encephalomyelitis/Chronic Fatigue Syndrome. 61
33092097 2020
41
Cardiac Dimensions and Function Are Not Altered among Females with the Myalgic Encephalomyelitis/Chronic Fatigue Syndrome. 61
33081294 2020
42
Early Growth Response Gene Upregulation in Epstein-Barr Virus (EBV)-Associated Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS). 61
33114612 2020
43
Reductions in Cerebral Blood Flow Can Be Provoked by Sitting in Severe Myalgic Encephalomyelitis/Chronic Fatigue Syndrome Patients. 61
33050553 2020
44
A SWATH-MS analysis of Myalgic Encephalomyelitis/Chronic Fatigue Syndrome peripheral blood mononuclear cell proteomes reveals mitochondrial dysfunction. 61
32972442 2020
45
Orthostatic stress testing in myalgic encephalomyelitis/chronic fatigue syndrome patients with or without concomitant fibromyalgia: effects on pressure pain thresholds and temporal summation. 61
32940215 2020
46
Neuroimaging characteristics of myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS): a systematic review. 61
32873297 2020
47
An analysis of 2-day cardiopulmonary exercise testing to assess unexplained fatigue. 61
32889791 2020
48
Using Plasma Autoantibodies of Central Nervous System Proteins to Distinguish Veterans with Gulf War Illness from Healthy and Symptomatic Controls. 61
32899468 2020
49
Genetic risk factors of ME/CFS: a critical review. 61
32744306 2020
50
Validation of the Severity of Myalgic Encephalomyelitis/Chronic Fatigue Syndrome by Other Measures than History: Activity Bracelet, Cardiopulmonary Exercise Testing and a Validated Activity Questionnaire: SF-36. 61
32823979 2020

Variations for Myalgic Encephalomyelitis/chronic Fatigue Syndrome

Expression for Myalgic Encephalomyelitis/chronic Fatigue Syndrome

Search GEO for disease gene expression data for Myalgic Encephalomyelitis/chronic Fatigue Syndrome.

Pathways for Myalgic Encephalomyelitis/chronic Fatigue Syndrome

Pathways related to Myalgic Encephalomyelitis/chronic Fatigue Syndrome according to GeneCards Suite gene sharing:

# Super pathways Score Top Affiliating Genes
1
Show member pathways
12.37 VEGFA RNASEL IL7 IL16
2
Show member pathways
11.01 RNASEL IL16 GDF15
3 10.23 IL7 IL16 GDF15

GO Terms for Myalgic Encephalomyelitis/chronic Fatigue Syndrome

Biological processes related to Myalgic Encephalomyelitis/chronic Fatigue Syndrome according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 cytokine-mediated signaling pathway GO:0019221 9.13 VEGFA IL7 IL16
2 induction of positive chemotaxis GO:0050930 8.62 VEGFA IL16

Molecular functions related to Myalgic Encephalomyelitis/chronic Fatigue Syndrome according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 growth factor activity GO:0008083 9.13 VEGFA IL7 GDF15
2 cytokine activity GO:0005125 8.92 VEGFA IL7 IL16 GDF15

Sources for Myalgic Encephalomyelitis/chronic Fatigue Syndrome

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
20 GARD
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
53 NINDS
54 Novoseek
56 OMIM via Orphanet
57 OMIM® (Updated 05-Mar-2021)
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 TGDB
70 Tocris
71 UMLS
72 UMLS via Orphanet
Content
Loading form....